Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Neoplasm Metastasis 3 Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Ovarian Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Breast Neoplasms, Male 1

Interventions

Doxorubicin 26 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Gemcitabine 13 Ifosfamide 12 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 X-Rays 8 Temozolomide 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 Blood Specimen Collection 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Lapatinib × 1 year × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡